Isthmus Partners LLC trimmed its stake in Iradimed Corporation (NASDAQ:IRMD - Free Report) by 20.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,818 shares of the medical equipment provider's stock after selling 14,846 shares during the period. Isthmus Partners LLC owned about 0.46% of Iradimed worth $2,908,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in IRMD. Liontrust Investment Partners LLP acquired a new stake in Iradimed during the second quarter worth about $2,830,000. Charles Schwab Investment Management Inc. lifted its position in shares of Iradimed by 189.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider's stock worth $3,351,000 after acquiring an additional 43,635 shares during the period. Oak Ridge Investments LLC acquired a new stake in shares of Iradimed during the 3rd quarter worth approximately $2,188,000. Eagle Asset Management Inc. bought a new stake in shares of Iradimed during the third quarter valued at approximately $1,239,000. Finally, Kings Path Partners LLC acquired a new position in shares of Iradimed in the second quarter valued at $1,055,000. Institutional investors own 92.34% of the company's stock.
Iradimed Trading Up 0.7 %
NASDAQ IRMD traded up $0.35 on Friday, reaching $53.93. The company's stock had a trading volume of 11,592 shares, compared to its average volume of 48,616. The firm has a market cap of $683.29 million, a PE ratio of 36.94 and a beta of 0.79. Iradimed Corporation has a 52 week low of $40.18 and a 52 week high of $57.95. The business has a 50-day moving average price of $51.60 and a 200 day moving average price of $47.12.
Iradimed Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a $0.15 dividend. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.11%. Iradimed's payout ratio is presently 41.10%.
Analyst Ratings Changes
Separately, Roth Mkm decreased their price target on shares of Iradimed from $65.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday, August 2nd.
Read Our Latest Report on Iradimed
About Iradimed
(
Free Report)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Featured Stories
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
